Sarepta Therapeutics, Inc. Income Statement

Income Statement Dec2009 Dec2010 Dec2011 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 46.99M37.33M14.22M9.76M1.25M5.42M154.58M301.03M380.83M540.10M701.89M933.01M1243.34M1901.98M
Cost of Revenue 0.10M7.35M34.19M56.59M63.38M97.05M139.99M150.34M319.10M
Gross Profit 46.99M37.33M14.22M9.76M1.25M5.32M147.23M266.84M324.25M476.72M604.84M793.02M1092.99M1582.88M
Operating items
Amortization - Intangibles 0.50M0.03M1.05M0.86M0.85M0.70M0.71M0.71M1.56M2.40M
Research & Development 66.86M52.40M72.91M94.23M146.39M188.27M166.71M401.84M560.91M722.34M771.18M877.09M877.39M804.52M
Selling, General & Administrative 16.05M14.63M31.59M49.31M75.04M83.75M122.68M207.76M284.81M317.88M282.66M451.42M481.87M557.87M
Other Operating Expenses 0.13M125.00M35.06M240.68M108.07M102.00M140.70M102.00M321.50M
Operating Expenses 82.92M67.03M104.50M143.55M221.44M272.15M326.22M644.66M1086.40M1104.26M1161.60M1469.21M1511.16M1683.90M
Operating Income -35.93M-29.70M-90.28M-133.79M-220.18M-266.73M-171.64M-343.63M-705.56M-564.16M-459.71M-536.20M-267.82M218.08M
EBIT -35.93M-29.70M-90.28M-133.79M-220.18M-266.73M-171.64M-343.63M-705.56M-564.16M-459.71M-536.20M-267.82M218.08M
Non-operating items
Interest & Investment Income 0.89M-0.54M1.81M6.81M7.24M2.97M0.35M16.49M36.26M
Other Non Operating Income 0.59M0.35M0.33M0.78M0.63M0.93M0.60M-0.66M-0.24M-61.24M-125.44M-387.33M42.69M
Non Operating Income 33.61M-91.58M-21.70M-2.00M0.15M0.93M123.01M-18.98M-8.32M11.10M-61.24M-153.76M-252.27M42.69M
Net income details
EBT -35.93M-29.70M-90.28M-133.79M-220.03M-267.26M-48.63M-362.61M-713.88M-553.07M-418.95M-689.96M-520.10M260.77M
Tax Provisions 2.06M-0.69M1.20M1.31M-0.17M14.14M16.04M25.78M
Profit After Tax -2.32M-121.29M-111.98M-135.79M-220.03M-267.26M-50.69M-361.92M-715.08M-554.13M-418.78M-703.49M-535.98M235.24M
Income from Continuing Operations -35.93M-29.70M-90.28M-133.79M-220.03M-267.26M-50.69M-361.92M-715.08M-554.37M-418.78M-704.10M-536.14M234.99M
Consolidated Net Income -35.93M-29.70M-90.28M-133.79M-220.03M-267.26M-50.69M-361.92M-715.08M-554.37M-418.78M-704.10M-536.14M234.99M
Income towards Parent Company -35.93M-29.70M-90.28M-133.79M-220.03M-267.26M-50.69M-361.92M-715.08M-554.37M-418.78M-704.10M-536.14M234.99M
Net Income towards Common Stockholders -35.93M-29.70M-90.28M-133.79M-220.03M-267.26M-50.69M-361.92M-715.08M-554.37M-418.78M-704.10M-536.14M234.99M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M0.00M
Shares Outstanding (Weighted Average) 18.41M18.72M22.62M25.45M37.58M41.31M45.27M54.59M64.63M66.82M74.54M78.91M87.08M87.78M93.55M95.52M
Shares Outstanding (Diluted Average) 129.59M
EBITDA -2.32M-121.29M-111.98M-135.88M-220.05M-267.27M-50.95M-361.64M-714.93M-554.17M-418.80M-705.13M-533.39M218.08M
Tax Rate 0.19%0.04%9.89%